Tandem Control-IQ Approved in Peds Down to 6 Years of Age
Tandem Diabetes Care announced the t:slim X2 insulin pump with Control-IQ has been approved by FDA for use in pediatric patients down to six years of age. Previously, the product was indicated for 14 years of age and older. Tandem senior management also presented at the 2020 Raymond James Healthcare Innovation Conference, providing brief commentary on the pediatric indication and market opportunity. Below, FENIX provides thoughts on the expanded indication from Medtronic, Insulet, Bigfoot, and Beta Bionics.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.